Chromatography ligand comprising domain C from Staphylococcus aureus protein A for antibody isolation

Patent metadata

Field	Value
Publication number	US-10343142-B2
Application number	US-201816189894-A
Country	US
Kind code	B2
Filing date	Nov 13, 2018
Priority date	Sep 29, 2006
Publication date	Jul 9, 2019
Grant date	Jul 9, 2019

Abstract

The present invention relates to a chromatography ligand, which comprises Domain C from Staphylococcus protein A (SpA), or a functional fragment or variant thereof. The chromatography ligand presents an advantageous capability of withstanding harsh cleaning in place (CIP) conditions, and is capable of binding Fab fragments of antibodies. The ligand may be provided with a terminal coupling group, such as arginine or cysteine, to facilitate its coupling to an insoluble carrier such as beads or a membrane. The invention also relates process of using the ligand in isolation of antibodies, and to a purification protocol which may include washing steps and/or regeneration with alkali.

First claim

What is claimed is:

1. A process for isolating one or more target compound(s), the process comprising:
(a) contacting a first liquid with a chromatography matrix, the first liquid comprising the target compound(s) and the chromatography matrix comprising:
(i) a solid support; and
(ii) at least one ligand coupled to the solid support, the ligand comprising at least two polypeptides, wherein the amino acid sequence of each polypeptide comprises at least 55 contiguous amino acids of a modified SEQ ID NO. 1, and wherein the modified SEQ ID NO. 1 has an alanine (A) instead of glycine (G) at a position corresponding to position 29 of SEQ ID NO. 1; and

(b) adsorbing the target compound(s) to the ligand; and,
(c) eluting the compound(s) by passing a second liquid through the chromatography matrix that releases the compound(s) from the ligand.

2. The process of claim 1 , wherein the ligand comprises 2-8 of the polypeptides, optionally coupled via linker segments.

3. The process of claim 1 , wherein the chromatography matrix is capable of retaining at least 95% of its original binding capacity after 5 hours incubation in 0.5 M NaOH.

4. The process of claim 1 , wherein the ligand binds to the Fab part of an antibody.

5. The process of claim 1 , wherein the ligand comprises a terminal coupling group comprising at least one nitrogen and/or sulfur atom(s).

6. The process of claim 5 , wherein the terminal group comprises arginine or cysteine.

7. The process of claim 1 , wherein the ligand is coupled to the solid support via thioether bonds.

8. The process of claim 1 , wherein the ligand further comprises one or more other alkaline-stable protein-based units.

9. The process of claim 1 , wherein the solid support is a polysaccharide.

10. The process of claim 1 , wherein the solid support is comprised of substantially spherical particles.

11. The process of claim 1 , wherein the solid support is porous.

12. The process of claim 1 , wherein the ligand comprises an amino acid sequence that comprises 2-8 of the polypeptides.

13. The process of claim 1 , wherein two or more ligands are coupled to the solid support.

14. A process for isolating one or more target compound(s), the process comprising:
(a) contacting a first liquid with a chromatography matrix, the first liquid comprising the target compound(s) and the chromatography matrix comprising:
(i) a solid support; and
(ii) a ligand coupled to the solid support, the ligand comprising at least two polypeptides, wherein the amino acid sequence of each polypeptide comprises at least 55 amino acids in alignment with SEQ ID NO. 1, and wherein each polypeptide has an alanine (A) instead of glycine (G) at a position corresponding to position 29 of SEQ ID NO. 1;

(b) adsorbing the target compound(s) to the ligand; and,
(c) eluting the compound(s) by passing a second liquid through the chromatography matrix that releases the compound(s) from the ligand.

15. The process of claim 14 , wherein the ligand comprises 2-8 of the polypeptides, optionally coupled via linker segments.

16. The process of claim 14 , wherein the chromatography matrix is capable of retaining at least 95% of its original binding capacity after 5 hours incubation in 0.5 M NaOH.

17. The process of claim 14 , wherein the ligand binds to the Fab part of an antibody.

18. The process of claim 14 , wherein the ligand comprises a terminal coupling group comprising at least one nitrogen and/or sulfur atom(s).

19. The process of claim 18 , wherein the terminal group comprises arginine or cysteine.

20. The process of claim 14 , wherein the ligand is coupled to the solid support via thioether bonds.

21. The process of claim 14 , wherein the ligand further comprises one or more other alkaline-stable protein-based units.

22. The process of claim 14 , wherein the solid support is a polysaccharide.

23. The process of claim 14 , wherein the solid support is comprised of substantially spherical particles.

24. The process of claim 14 , wherein the solid support is porous.

25. The process of claim 14 , wherein the ligand comprises an amino acid sequence that comprises 2-8 of the polypeptides.

26. The process of claim 14 , wherein two or more ligands are coupled to the solid support.

27. The process of claim 1 , further comprising a step of exposing the chromatography matrix to 0.1 to 0.5 M NaOH.

28. The process of claim 27 , further comprising repeated exposure of the chromatography matrix to the NaOH for at least 80 cycles.

29. The process of claim 14 , further comprising a step of exposing the chromatography matrix to 0.1 to 0.5 M NaOH.

30. The process of claim 29 , further comprising repeated exposure of the chromatography matrix to the NaOH for at least 80 cycles.

Assignees

• Ge Healthcare Bioprocess R&D Ab

Inventors

• Hall Martin
• Larsson Sture
• Muranyi Andreas
• Rodrigo Gustav
• Zou Jinyu
• Aberg Per-Mikael

Classifications

• B01J20/3274

  Proteins, nucleic acids, polysaccharides, antibodies or antigens · CPC title

• B01D15/3809 Primary

  of the antigen-antibody type, e.g. protein A, G or L chromatography · CPC title

• C07K14/31

  from Staphylococcus (G) · CPC title

• C07K1/22

  Affinity chromatography or related techniques based upon selective absorption processes · CPC title

• B01J20/24 Primary

  Naturally occurring macromolecular compounds, e.g. humic acids or their derivatives · CPC title